
Takeda Pharmaceutical (4502.T) Revenue
Market Cap: $7.20T
Avg Volume: 4.11M
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
What is Takeda Pharmaceutical's Revenue?
Takeda Pharmaceutical's quarterly revenue as of Q3 2024 is $1.14T.
Takeda Pharmaceutical's annual revenue for the fiscal year 2023 is $4.26T.
Related metrics for Takeda Pharmaceutical (quarterly):
- Cost of Revenue: $416.87B
- Gross Profit: $727.25B
- Gross Profit Ratio: 63.56%
- Revenue Per Share: $722.69
- Revenue Growth: -2.71%
Apple's quarterly revenue was $1.14T, with a cost of revenue of $416.87B, which leaves $727.25B gross profit and a gross profit ratio of 63.56%.
Related metrics for Takeda Pharmaceutical (annual):
- Cost of Revenue: $1.43T
- Gross Profit: $2.83T
- Gross Profit Ratio: 66.43%
- Revenue Per Share: $2725.41
- Revenue Growth: 5.87%
Apple's annual revenue was $4.26T, with a cost of revenue of $1.43T, which leaves $2.83T gross profit and a gross profit ratio of 66.43%.
Understanding Revenue
Revenue is the total amount of income generated by the sale of goods or services related to the company's primary operations. It is often referred to as the "top line" because it sits at the top of the income statement.
End of Year Revenue
The table below shows the revenue for each fiscal year, with the latest data available for 2023.
Year | Revenue | Change |
---|---|---|
2023 | $4.26T | 5.87% |
2022 | $4.03T | 12.85% |
2021 | $3.57T | 11.61% |
2020 | $3.20T | -2.84% |
2019 | $3.29T | 56.93% |
2018 | $2.10T | 18.45% |
2017 | $1.77T | 2.22% |
2016 | $1.73T | -4.17% |
2015 | $1.81T | 1.66% |
2014 | $1.78T | 5.09% |
2013 | $1.69T | 8.63% |
2012 | $1.56T | 3.20% |
2011 | $1.51T | 6.31% |
2010 | $1.42T | -3.18% |
2009 | $1.47T | -4.70% |
2008 | $1.54T | 11.90% |
2007 | $1.37T | 5.34% |
2006 | $1.31T | 7.67% |
2005 | $1.21T | 7.95% |
2004 | $1.12T | 3.36% |
2003 | $1.09T | 3.86% |
2002 | $1.05T | 4.08% |
2001 | $1.01T | 4.32% |
2000 | $963.48B | 4.37% |
1999 | $923.13B | N/A |
Related Metrics
Explore detailed financial metrics and analysis for 4502.T.